Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies

Deepaneeta Sarmah; Vishal Agrawal; Pallavi Rane; Shashikala Bhute; Mitsuyoshi Watanabe; Kiran Kalia; Zhumur Ghosh; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya

doi:10.1002/cpt.927

Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies

Deepaneeta Sarmah, Vishal Agrawal, Pallavi Rane, Shashikala Bhute, Mitsuyoshi Watanabe, Kiran Kalia, Zhumur Ghosh, Kunjan R Dave, Dileep R Yavagal, Pallab Bhattacharya

Neurology

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.

Original language	English (US)
Journal	Clinical Pharmacology and Therapeutics
DOIs	https://doi.org/10.1002/cpt.927
State	Accepted/In press - Jan 1 2017

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.927

Fingerprint Dive into the research topics of 'Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies'. Together they form a unique fingerprint.

Cite this

Mesenchymal Stem Cell Therapy in Ischemic Stroke : A Meta-analysis of Preclinical Studies. / Sarmah, Deepaneeta; Agrawal, Vishal; Rane, Pallavi; Bhute, Shashikala; Watanabe, Mitsuyoshi; Kalia, Kiran; Ghosh, Zhumur; Dave, Kunjan R ; Yavagal, Dileep R; Bhattacharya, Pallab.

In: Clinical Pharmacology and Therapeutics, 01.01.2017.

Research output: Contribution to journal › Article › peer-review

@article{fc6d265fbb7f49bd93c11bb3555f335b,

title = "Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies",

abstract = "Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.",

author = "Deepaneeta Sarmah and Vishal Agrawal and Pallavi Rane and Shashikala Bhute and Mitsuyoshi Watanabe and Kiran Kalia and Zhumur Ghosh and Dave, {Kunjan R} and Yavagal, {Dileep R} and Pallab Bhattacharya",

year = "2017",

month = jan,

day = "1",

doi = "10.1002/cpt.927",

language = "English (US)",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Mesenchymal Stem Cell Therapy in Ischemic Stroke

T2 - A Meta-analysis of Preclinical Studies

AU - Sarmah, Deepaneeta

AU - Agrawal, Vishal

AU - Rane, Pallavi

AU - Bhute, Shashikala

AU - Watanabe, Mitsuyoshi

AU - Kalia, Kiran

AU - Ghosh, Zhumur

AU - Dave, Kunjan R

AU - Yavagal, Dileep R

AU - Bhattacharya, Pallab

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.

AB - Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=85038015460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038015460&partnerID=8YFLogxK

U2 - 10.1002/cpt.927

DO - 10.1002/cpt.927

M3 - Article

C2 - 29090465

AN - SCOPUS:85038015460

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -